Indian brokerages put out five short-term buy calls for Tuesday’s session, with combined upside targets averaging just 3.4% and stop-losses kept inside 2.1% on the median trade. The picks lean heavily on private banking, IT services, the BSE exchange itself and a defensive pharma name, after the Sensex closed Monday at 75,687, up 0.49%, and the Nifty 50 inched higher to 23,649.95.
That cautious spread of targets is the read worth taking. Brokers from BlueOak Wealth, HDFC Securities and PL Capital all flagged buyable setups, yet none asked for more than 5.1% before booking out. Behind the table sits a fragile macro backdrop: the rupee at a record 96.20 against the dollar, Iran tensions easing only this week, and Nifty IT bellwethers still down close to a quarter on the year.
The Setup for Tuesday’s Session
After Monday’s choppy trade, the late recovery in IT stocks did most of the heavy lifting. The Sensex clawed back 1,135 points from intraday lows. TCS, Infosys, HCL Tech and Persistent rose between 3.4% and 4.5%, the kind of single-day rally that follows a brutal stretch rather than starts a fresh leg up. Monday’s tape showed how a one-sector chase-down can paper over weakness elsewhere, with metals, PSU banks and power capping the upside.
Iran-Israel tensions have moved from acute to merely simmering. US President Donald Trump’s signal that he had paused a planned strike on Tehran, in exchange for a peace overture tied to Iran’s nuclear program, lifted Indian risk assets at the open on Monday. That same easing took some pressure off Brent crude and gave the rupee a brief reprieve, though both reversals look fragile from where they sit on Tuesday morning.
The macro is doing two opposing things to Indian equities at once. A weak rupee, hovering near 96.20 to the dollar, mechanically boosts the reported revenues of Indian IT exporters paid in dollars; the same currency move has forced Delhi to pull four policy levers at once to defend household budgets. Persistent worry that generative AI tools are starting to compress traditional outsourcing contracts has kept Nifty IT down through the first half of 2026.
Private financials face the opposite pull. ICICI Bank closed Monday near ₹1,237, just below the buy entry recommended for Tuesday, after the lender posted full-year net profit of ₹54,207.70 crore for FY26, a 6.23% rise on the prior year. Earnings visibility, not multiple expansion, is the pitch.
The Five Calls at a Glance
Across the recommendations, the median target sits roughly 3.1% above entry and the median stop-loss sits 1.8% below. The widest swing comes from BSE Ltd, where Amit Goel of BlueOak Wealth flagged 5.13% upside but accepted 3.29% downside risk to play it. Sun Pharmaceutical Industries carries the tightest target, with only ₹45 separating entry and the first profit-take.
| Stock | Entry (₹) | Target (₹) | Stop-Loss (₹) | Upside | Risk-Reward |
|---|---|---|---|---|---|
| BSE Ltd | 4,074 | 4,283 | 3,940 | +5.13% | 1.56 |
| Infosys | 1,142 | 1,177 | 1,118 | +3.06% | 1.46 |
| Sun Pharma | 1,905 | 1,950 | 1,870 | +2.36% | 1.29 |
| ICICI Bank | 1,240 | 1,280 | 1,225 | +3.23% | 2.67 |
| Coforge | 1,348 | 1,390 | 1,325 | +3.12% | 1.83 |
The structure tells you something. ICICI Bank carries the strongest risk-reward at 2.67, because the recommended stop-loss is unusually tight at ₹1,225. Sun Pharma carries the weakest at 1.29, reflecting a target sitting only ₹45 above entry. None of the calls assume more than a single-week move; these are deliverable technical setups, not multi-month theses.
The names also cluster. Three of the five sit in financials or the financial-market plumbing (BSE, ICICI Bank, and the exchange operator itself), and two sit in IT services. There is one pharmaceutical pick and zero from autos, metals, energy or PSU banks, the four sectors that have drifted or fallen the hardest through May. Sector rotation, by omission rather than by speech.
Inside BSE’s Earnings Engine
The exchange operator is the only call on the list whose underlying business has accelerated through 2026 rather than slowed. BSE Ltd’s audited financial results filings show the holding company that owns Asia’s oldest stock exchange riding a wave of derivatives volumes and a record IPO pipeline into a year of triple-digit profit growth.
- ₹797.33 crore net profit in Q4 FY26, up 61.27% year-on-year, per the audited results released on May 8, 2026
- ₹1,563.51 crore revenue in the same quarter, up 84.67% on a year earlier
- ₹601.81 crore net profit in Q3 FY26, a 173.96% jump on the comparable quarter of FY25
Derivatives volumes have been the engine. The exchange’s market share in equity options notional turnover has climbed steadily through FY26, narrowing the gap with NSE (National Stock Exchange) that defined the prior decade. Index option contracts on Bankex and Sensex have absorbed retail flow that previously sat at the rival exchange.
Amit Goel, Partner and Co-Founder at BlueOak Wealth and a SEBI-registered research analyst, sees the technical chart matching the fundamental run. The buy is at ₹4,074, the target ₹4,283, the stop-loss ₹3,940. By mid-morning on Monday, the stock had already traded at ₹4,264, within striking distance of the level Goel wanted for Tuesday.
The catch is that the exchange has compounded too quickly for comfort. The stock has roughly tripled from its mid-2024 levels, and any earnings disappointment in subsequent quarters would arrive against a still-elevated multiple.
The IT Trade With Stocks Near Year Lows
Both IT recommendations sit on charts that look broken by any twelve-month frame. Infosys is down 23.98% over the last six months and 29.17% over the last year. Coforge has dropped 24.43% in six months. Brokers are not calling a turn here; they are calling a bounce inside a downtrend.
Infosys: Riding a Single-Day Rally
Goel’s entry for the IT major is ₹1,142 against a target of ₹1,177, a 3.06% move, with a stop-loss at ₹1,118. The technical case rests on Monday’s IT rally, where the stock gained between 3.4% and 4.5% alongside TCS and HCL Tech. The fundamental backdrop is messier. PL Capital still rates the company a long-term buy at ₹1,570; Goldman Sachs sits Neutral at a target of ₹1,290. Both lap the current price by a wide margin, and neither matches the modest target in Tuesday’s setup. Goel is playing the bounce, not the thesis.
Coforge: The Mid-Cap Bounce Trade
Vinay Rajani, Senior Technical Research Analyst at HDFC Securities, sees Coforge moving from ₹1,348 to ₹1,390, a 3.12% gain, with a stop at ₹1,325. The Noida-based digital-services company posted topline growth of about 30% year-on-year in Q4 FY26, with the Healthcare vertical revenue up 78.4% and Travel and Hospitality up 59.2%, per Coforge’s investor disclosures. Yet the stock trades a quarter below its November 2025 level. Axis Direct’s twelve-month target sits at ₹1,690, suggesting analysts believe the fundamentals have pulled away from the share price.
The IT pair shares a thesis: weak rupee plus an oversold chart equals a tactical bounce. Neither call rests on a turn in the AI-disruption narrative that has weighed on the sector since late 2025. If the rupee retraces back toward 95.50 against the dollar, the export-revenue tailwind softens and both trades lose their easiest support.
Sun Pharma and ICICI Bank: The Defensive Pair
The remaining two calls share a profile unusual on a technical trade list: both are large-cap names with stable earnings, defensive sector beta, and limited charting drama. Rajani sees Sun Pharma moving from ₹1,905 to ₹1,950, a 2.36% gain, with a stop-loss at ₹1,870. That is the tightest reward target on the page, and it lands four trading days before the company’s next earnings report on May 22.
The pharma setup is a momentum continuation. The 12-month analyst consensus price target sits at ₹1,992, with the highest estimate at ₹2,528 and the lowest at ₹1,650, per 32 covering analysts. Buying at ₹1,905 for a ₹45 move is a calibrated bet that the chart holds into the earnings print, not a long thesis on Sun’s specialty pipeline. The stock has held the top of a three-month range that built after the February correction in pharma names.
The private bank pick is the most asymmetric trade in the basket. Vaishali Parekh, Vice President of Technical Research at PL Capital, set entry at ₹1,240, target ₹1,280, and a stop-loss at ₹1,225, just ₹15 below the entry. The implied risk-reward ratio of 2.67 is the highest among the five recommendations. ICICI closed Monday at ₹1,237.90, down 1.06% on the session, slightly below the buy zone.
What backs Parekh’s call is foreign-investor flow rather than technical momentum alone. Foreign institutional investors have continued to favour large private banks for earnings visibility, treating PSU peers with caution. The lender’s full-year FY26 net profit growth of 6.23% sits below its own five-year average, yet remains the cleanest visible-earnings story across listed Indian banks of comparable size.
The Risk-Reward Math
Aggregated, the basket offers modest absolute upside and very modest absolute risk. The arithmetic average upside is 3.38%; the arithmetic average downside (entry to stop-loss) is 2.03%. That blends to an average reward-to-risk ratio near 1.83 across the five calls, with the private bank pulling the average up and the pharma name pulling it down.
Three caveats sit underneath the numbers:
- All five recommendations are technical short-term trades, not investment theses; the implicit holding period is days, not quarters
- The two IT calls are tactical bounce plays on stocks still down roughly a quarter over six months; a missed target may not signal a reversal so much as a continuation of the existing downtrend
- The exchange operator’s near-50% earnings beat in Q4 FY26 is already partially in the price; the trade banks on momentum extending another five points, not on a re-rating
Tuesday’s calendar is light by Indian standards, with no scheduled major data prints, no Reserve Bank of India announcements and no large earnings releases. That puts the burden squarely on technical levels, foreign flows and the rupee. If the Nifty 50 holds above 23,500 through the next two sessions and the rupee stops weakening past 96.50, the basket has room to print its averages. If the rupee cracks further or Sun Pharma’s May 22 print lands soft, the tighter stop-losses on the pharma and mid-cap IT names will trigger first, before the defensive book catches up.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Stock recommendations referenced here are short-term technical calls made by named research analysts at their respective firms, not endorsements; equity investments carry the risk of capital loss. Readers should consult a SEBI-registered investment adviser before acting on any recommendation. Prices and analyst targets are accurate as of publication on May 19, 2026.
